![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAP3K14 |
Gene summary for MAP3K14 |
![]() |
Gene information | Species | Human | Gene symbol | MAP3K14 | Gene ID | 9020 |
Gene name | mitogen-activated protein kinase kinase kinase 14 | |
Gene Alias | FTDCR1B | |
Cytomap | 17q21.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q68D39 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9020 | MAP3K14 | RNA-P17T-P17T-2 | Human | Lung | IAC | 6.84e-03 | 5.27e-01 | 0.3371 |
9020 | MAP3K14 | RNA-P17T-P17T-4 | Human | Lung | IAC | 5.14e-05 | 5.12e-01 | 0.343 |
9020 | MAP3K14 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.97e-06 | 6.67e-01 | 0.3385 |
9020 | MAP3K14 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.45e-04 | 3.44e-01 | -0.0166 |
9020 | MAP3K14 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.25e-05 | 3.39e-01 | -0.0132 |
9020 | MAP3K14 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 6.18e-09 | 4.10e-01 | -0.013 |
9020 | MAP3K14 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.37e-03 | 2.85e-01 | -0.0121 |
9020 | MAP3K14 | C30 | Human | Oral cavity | OSCC | 1.14e-12 | 5.51e-01 | 0.3055 |
9020 | MAP3K14 | C46 | Human | Oral cavity | OSCC | 1.04e-10 | 4.00e-01 | 0.1673 |
9020 | MAP3K14 | LN46 | Human | Oral cavity | OSCC | 9.60e-13 | 5.01e-01 | 0.1666 |
9020 | MAP3K14 | EOLP-1 | Human | Oral cavity | EOLP | 9.19e-03 | 1.55e-01 | -0.0202 |
9020 | MAP3K14 | SYSMH2 | Human | Oral cavity | OSCC | 1.41e-04 | 2.58e-01 | 0.2326 |
9020 | MAP3K14 | SYSMH3 | Human | Oral cavity | OSCC | 1.49e-03 | 1.73e-01 | 0.2442 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00072495 | Lung | IAC | I-kappaB kinase/NF-kappaB signaling | 56/2061 | 281/18723 | 7.39e-06 | 2.62e-04 | 56 |
GO:00431226 | Lung | IAC | regulation of I-kappaB kinase/NF-kappaB signaling | 51/2061 | 249/18723 | 8.41e-06 | 2.87e-04 | 51 |
GO:00714968 | Lung | IAC | cellular response to external stimulus | 60/2061 | 320/18723 | 2.50e-05 | 6.76e-04 | 60 |
GO:00431235 | Lung | IAC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 38/2061 | 186/18723 | 1.19e-04 | 2.25e-03 | 38 |
GO:00712146 | Lung | IAC | cellular response to abiotic stimulus | 58/2061 | 331/18723 | 2.30e-04 | 3.96e-03 | 58 |
GO:01040046 | Lung | IAC | cellular response to environmental stimulus | 58/2061 | 331/18723 | 2.30e-04 | 3.96e-03 | 58 |
GO:00096156 | Lung | IAC | response to virus | 61/2061 | 367/18723 | 6.75e-04 | 9.12e-03 | 61 |
GO:00096125 | Lung | IAC | response to mechanical stimulus | 39/2061 | 216/18723 | 1.29e-03 | 1.45e-02 | 39 |
GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:010400416 | Oral cavity | OSCC | cellular response to environmental stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:00712605 | Oral cavity | OSCC | cellular response to mechanical stimulus | 52/7305 | 81/18723 | 3.86e-06 | 4.55e-05 | 52 |
GO:000961210 | Oral cavity | OSCC | response to mechanical stimulus | 115/7305 | 216/18723 | 1.43e-05 | 1.44e-04 | 115 |
GO:00380614 | Oral cavity | OSCC | NIK/NF-kappaB signaling | 78/7305 | 143/18723 | 1.14e-04 | 8.35e-04 | 78 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520816 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
hsa0516616 | Lung | IAC | Human T-cell leukemia virus 1 infection | 49/1053 | 222/8465 | 3.44e-05 | 6.38e-04 | 4.24e-04 | 49 |
hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa051205 | Lung | IAC | Epithelial cell signaling in Helicobacter pylori infection | 20/1053 | 70/8465 | 2.31e-04 | 2.54e-03 | 1.68e-03 | 20 |
hsa04625 | Lung | IAC | C-type lectin receptor signaling pathway | 26/1053 | 104/8465 | 3.15e-04 | 3.11e-03 | 2.06e-03 | 26 |
hsa042107 | Lung | IAC | Apoptosis | 30/1053 | 136/8465 | 1.11e-03 | 7.82e-03 | 5.19e-03 | 30 |
hsa0516916 | Lung | IAC | Epstein-Barr virus infection | 40/1053 | 202/8465 | 1.72e-03 | 9.66e-03 | 6.41e-03 | 40 |
hsa046685 | Lung | IAC | TNF signaling pathway | 25/1053 | 114/8465 | 3.01e-03 | 1.53e-02 | 1.02e-02 | 25 |
hsa04380 | Lung | IAC | Osteoclast differentiation | 27/1053 | 128/8465 | 3.74e-03 | 1.84e-02 | 1.22e-02 | 27 |
hsa04660 | Lung | IAC | T cell receptor signaling pathway | 23/1053 | 104/8465 | 3.88e-03 | 1.88e-02 | 1.25e-02 | 23 |
hsa049364 | Lung | IAC | Alcoholic liver disease | 29/1053 | 142/8465 | 4.45e-03 | 2.07e-02 | 1.37e-02 | 29 |
hsa0520817 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
hsa0516617 | Lung | IAC | Human T-cell leukemia virus 1 infection | 49/1053 | 222/8465 | 3.44e-05 | 6.38e-04 | 4.24e-04 | 49 |
hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0512012 | Lung | IAC | Epithelial cell signaling in Helicobacter pylori infection | 20/1053 | 70/8465 | 2.31e-04 | 2.54e-03 | 1.68e-03 | 20 |
hsa046251 | Lung | IAC | C-type lectin receptor signaling pathway | 26/1053 | 104/8465 | 3.15e-04 | 3.11e-03 | 2.06e-03 | 26 |
hsa0421012 | Lung | IAC | Apoptosis | 30/1053 | 136/8465 | 1.11e-03 | 7.82e-03 | 5.19e-03 | 30 |
hsa0516917 | Lung | IAC | Epstein-Barr virus infection | 40/1053 | 202/8465 | 1.72e-03 | 9.66e-03 | 6.41e-03 | 40 |
hsa0466812 | Lung | IAC | TNF signaling pathway | 25/1053 | 114/8465 | 3.01e-03 | 1.53e-02 | 1.02e-02 | 25 |
hsa043801 | Lung | IAC | Osteoclast differentiation | 27/1053 | 128/8465 | 3.74e-03 | 1.84e-02 | 1.22e-02 | 27 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K14 | SNV | Missense_Mutation | rs371527687 | c.2576N>G | p.Asn859Ser | p.N859S | Q99558 | protein_coding | deleterious(0.03) | possibly_damaging(0.637) | TCGA-A6-6648-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
MAP3K14 | SNV | Missense_Mutation | novel | c.1921N>T | p.Arg641Cys | p.R641C | Q99558 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
MAP3K14 | SNV | Missense_Mutation | rs199558586 | c.653G>A | p.Arg218Gln | p.R218Q | Q99558 | protein_coding | tolerated_low_confidence(0.47) | benign(0) | TCGA-AA-3875-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K14 | SNV | Missense_Mutation | rs370661357 | c.973C>T | p.Arg325Cys | p.R325C | Q99558 | protein_coding | deleterious_low_confidence(0.04) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
MAP3K14 | SNV | Missense_Mutation | rs755630489 | c.2081N>T | p.Ser694Leu | p.S694L | Q99558 | protein_coding | tolerated(0.16) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MAP3K14 | SNV | Missense_Mutation | novel | c.1780C>T | p.His594Tyr | p.H594Y | Q99558 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AY-A69D-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K14 | SNV | Missense_Mutation | novel | c.1148N>T | p.Thr383Ile | p.T383I | Q99558 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K14 | SNV | Missense_Mutation | novel | c.632A>T | p.Lys211Met | p.K211M | Q99558 | protein_coding | deleterious_low_confidence(0.02) | benign(0.241) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP3K14 | SNV | Missense_Mutation | novel | c.2626C>T | p.Arg876Trp | p.R876W | Q99558 | protein_coding | tolerated(0.07) | benign(0.443) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MAP3K14 | SNV | Missense_Mutation | rs55820104 | c.86N>T | p.Thr29Met | p.T29M | Q99558 | protein_coding | tolerated_low_confidence(0.08) | benign(0.143) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9020 | MAP3K14 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 374883851 | ||
9020 | MAP3K14 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 374883852 | ||
9020 | MAP3K14 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 249565854 | ||
9020 | MAP3K14 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 405560388 |
Page: 1 |